Inhibin B as a biomarker for ovarian reserve and ovarian response: systematic reviews and meta-analyses of diagnostic test accuracy.
Danlin Wang, Li Wang, Yan Fang
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed the diagnostic accuracy of inhibin B compared with anti-Müllerian hormone (AMH) for ovarian reserve and ovarian response. Eight studies comprising 12 datasets and 2878 women were included. For ovarian reserve, inhibin B had sensitivity of 0.69, specificity of 0.88, and an SROC AUC of 0.89; for ovarian response, the corresponding values were 0.60, 0.79, and 0.77. Sensitivity was significantly higher for ovarian reserve than for response (P < 0.001). The authors judged accuracy moderate for reserve and lower for response, with AMH remaining superior.
Key findings
- For ovarian reserve, inhibin B sensitivity was 0.69, specificity was 0.88, and DOR was 16.52.
- For ovarian response, inhibin B sensitivity was 0.60, specificity was 0.79, and DOR was 5.80.
- SROC AUC was 0.89 for ovarian reserve and 0.77 for ovarian response.
- Sensitivity was significantly higher for ovarian reserve than for ovarian response (P < 0.001).
Why it matters
The findings distinguish inhibin B’s diagnostic performance across two related but different assessments: it performed better for ovarian reserve than for ovarian response. This helps frame its potential role in evaluation and underscores that diagnostic accuracy is not equivalent across outcomes. The review’s conclusion that AMH remains superior is relevant when interpreting inhibin B as a biomarker.
What to keep in mind
The evidence base comprised eight studies and 12 datasets; the abstract does not report further limitations.